Jay Datukan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jay Datukan has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Do Huyen Nga
Department of Hematologic Oncology, Vietnam National Cancer Hospital, Hanoi, Vietnam
3 shared publications - Eric Tse
University of Hong Kong 16 , Hong Kong, Hong Kong SAR, China
3 shared publications Priscilla Caguioa
3 shared publicationsSuporn Chuncharunee
3 shared publications- Ayumi Fujimoto
Division of Hematology and Oncology, Department of Internal Medicine, Faculty of Medicine, Shimane University, Izumo, Japan
2 shared publications - Choon Kiat Ong
Duke-NUS Medical School, Singapore, Singapore
2 shared publications
Latest Publications
- Open Access
- 10 March 2026
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (2)
Understanding the practice landscape of marginal zone lymphoma in Southeast and East Asia
- 10 March 2026
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (2)
Open AccessUnderstanding the practice landscape of marginal zone lymphoma in Southeast and East Asia
- 1 October 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2500288
Advanced Classical Hodgkin Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group
PURPOSE: The management of advanced classical Hodgkin lymphoma (cHL) poses a major challenge in Asia, given disparities in health care resources and the variability in health care systems across the region. This article reviews the practice landscape for advanced cHL in East and Southeast Asia (hereafter referred to as Asia), offers detailed perspectives on the challenges faced by treating physicians, and proposes solutions to improve patient outcomes. METHODS: At the Singapore Lymphoma Scientific Symposium 2024, a panel of lymphoma experts from 10 countries/territories across Asia convened to discuss local cHL management practices. Discussions were supplemented by perspectives from an expert from the United States and a review of published literature on HL in Asia in 2014-2024. This article summarizes meeting discussions and reports relevant aspects of Asian practice preferences for advanced cHL. RESULTS: In Asia, cHL management is hindered by the lack of local guidelines and survivorship programs, challenges in diagnosis and staging because of a lack of resources and funding, and limited access to efficacious novel drugs. This is of particular concern in vulnerable patient populations such as the elderly. To uplift the standard of care for patients with cHL locally, greater cross-regional learning and collaboration could be explored to enhance clinical management capabilities, lower the financial barriers to accessing novel drugs and technologies, and support increased research efforts and clinical trial presence in the region. CONCLUSION: Although advanced cHL management remains a challenge in Asia because of diverse needs within the region, regional partnerships and initiatives can bridge existing gaps and supplement local efforts to improve outcomes among patients with advanced cHL.
- 1 October 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2500288
Advanced Classical Hodgkin Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group
PURPOSE: The management of advanced classical Hodgkin lymphoma (cHL) poses a major challenge in Asia, given disparities in health care resources and the variability in health care systems across the region. This article reviews the practice landscape for advanced cHL in East and Southeast Asia (hereafter referred to as Asia), offers detailed perspectives on the challenges faced by treating physicians, and proposes solutions to improve patient outcomes. METHODS: At the Singapore Lymphoma Scientific Symposium 2024, a panel of lymphoma experts from 10 countries/territories across Asia convened to discuss local cHL management practices. Discussions were supplemented by perspectives from an expert from the United States and a review of published literature on HL in Asia in 2014-2024. This article summarizes meeting discussions and reports relevant aspects of Asian practice preferences for advanced cHL. RESULTS: In Asia, cHL management is hindered by the lack of local guidelines and survivorship programs, challenges in diagnosis and staging because of a lack of resources and funding, and limited access to efficacious novel drugs. This is of particular concern in vulnerable patient populations such as the elderly. To uplift the standard of care for patients with cHL locally, greater cross-regional learning and collaboration could be explored to enhance clinical management capabilities, lower the financial barriers to accessing novel drugs and technologies, and support increased research efforts and clinical trial presence in the region. CONCLUSION: Although advanced cHL management remains a challenge in Asia because of diverse needs within the region, regional partnerships and initiatives can bridge existing gaps and supplement local efforts to improve outcomes among patients with advanced cHL.
- 1 October 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2500353
Peripheral T-Cell Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group
PURPOSE: Peripheral T-cell lymphomas (PTCLs) encompass a group of rare and diverse disease entities for which contemporary frontline treatment options are limited. Patient outcomes for PTCL remain poor globally, and disparities in health care resources and health care system variability across East and Southeast Asia (hereafter referred to as Asia) further complicate PTCL management in the region. This article reviews the practice landscape for PTCL in Asia, provides a nuanced perspective on the challenges faced by physicians in the region, and suggests how patient outcomes can be improved. METHODS: A panel of lymphoma experts from 10 countries/territories across Asia convened at the Singapore Lymphoma Scientific Symposium 2024 to discuss local PTCL management practices. Discussions were supplemented by perspectives from an expert from the United States and a review of published literature on PTCL in Asia in the past 10 years. Meeting discussions and relevant aspects of Asian PTCL practice preferences are summarized in this article. RESULTS: In Asia, PTCL diagnosis and management are hindered by the lack of available domain experts, limitations in infrastructure support and funding, and substantial challenges in accessing novel drugs; relapsed/refractory PTCL, in particular, remains an area of great clinical unmet need. To improve the standard of care for patients with PTCL, cross-country collaborative efforts will be required to facilitate cross-border knowledge sharing, enhance access to expertise and specialized pathology services, increase local clinical trial presence, and offer educational and research opportunities. CONCLUSION: Significant challenges remain for PTCL management in Asia. Concerted efforts to enhance diagnostic accuracy, improve access to innovative therapies, and establish robust international partnerships are crucial for achieving better outcomes for patients with PTCL in the region.
- 1 October 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2500353
Peripheral T-Cell Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group
PURPOSE: Peripheral T-cell lymphomas (PTCLs) encompass a group of rare and diverse disease entities for which contemporary frontline treatment options are limited. Patient outcomes for PTCL remain poor globally, and disparities in health care resources and health care system variability across East and Southeast Asia (hereafter referred to as Asia) further complicate PTCL management in the region. This article reviews the practice landscape for PTCL in Asia, provides a nuanced perspective on the challenges faced by physicians in the region, and suggests how patient outcomes can be improved. METHODS: A panel of lymphoma experts from 10 countries/territories across Asia convened at the Singapore Lymphoma Scientific Symposium 2024 to discuss local PTCL management practices. Discussions were supplemented by perspectives from an expert from the United States and a review of published literature on PTCL in Asia in the past 10 years. Meeting discussions and relevant aspects of Asian PTCL practice preferences are summarized in this article. RESULTS: In Asia, PTCL diagnosis and management are hindered by the lack of available domain experts, limitations in infrastructure support and funding, and substantial challenges in accessing novel drugs; relapsed/refractory PTCL, in particular, remains an area of great clinical unmet need. To improve the standard of care for patients with PTCL, cross-country collaborative efforts will be required to facilitate cross-border knowledge sharing, enhance access to expertise and specialized pathology services, increase local clinical trial presence, and offer educational and research opportunities. CONCLUSION: Significant challenges remain for PTCL management in Asia. Concerted efforts to enhance diagnostic accuracy, improve access to innovative therapies, and establish robust international partnerships are crucial for achieving better outcomes for patients with PTCL in the region.